“Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis”, J of Skin, vol. 10, no. 2, p. s729, Mar. 2026, doi: 10.25251/1jtrf706.